


I hereby certify that this correspondence is being electronically filed in the United States Patent and Trademark Office on June 11, 2009.



Frank C. Eisenschenk, Ph.D., Patent Attorney

SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT  
Patent Application  
Docket No. BKR.110T

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Xiaozhen Xie, Ph.D.  
Art Unit : 1646  
Applicants : Michel Christian Morre, Brigitte Assouline, Pierre Cortez, Anne Gregoire  
Serial No. : 10/522,883  
Filed : April 18, 2005  
Conf. No. : 9491  
For : IL-7 Drug Substance, Composition, Preparation and Uses

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR §§1.97 AND 1.98

Sir:

In accordance with 37 CFR §1.56, the reference listed on the attached form PTO/SB/08 is being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. Applicants have not submitted a copy of the published U.S. Patent Application cited on attached Form PTO/SB/08 pursuant to 37 CFR 1.98(a)(2)(ii).

It is respectfully requested that the reference cited on the attached form PTO/SB/08 be considered in the examination of the subject application and that its consideration be made of record.

Applicants respectfully assert that the substantive provisions of 37 C.F.R. §§ 1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.  
Patent Attorney  
Registration No. 45,332  
Phone No.: 352-375-8100  
Fax No.: 352-372-5800  
Address: P.O. Box 142950  
Gainesville, FL 32614-2950

FCE/sl  
Attachment: Form PTO/SB/08